Hormone Insight Editorial Team
Clinical archive
Does Exenatide Help After Heart Surgery?
A large RCT finds peri-operative exenatide does not reduce death or organ failure after CABG or aortic valve replacement. PICO summary and expert commentary.
Is the Dulaglutide Biosimilar LY05008 Equivalent to Trulicity in Chinese Adults With Type 2 Diabetes?
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 equivalent to reference dulaglutide (Trulicity) for HbA1c reduction at 24 weeks. PICO summary and expert commentary.
Does Tirzepatide Boost Fat Burning Without Changing Metabolism?
A phase 1 mechanistic study in adults with obesity found tirzepatide did not alter metabolic adaptation but increased fat oxidation and reduced calorie intake versus placebo. PICO summary and expert commentary.
Does a GPR119 Agonist Help Glucagon Response in Type 1 Diabetes?
A phase 2a crossover trial finds the GPR119 agonist MBX-2982 does not improve glucagon counterregulation in type 1 diabetes, despite target engagement. PICO summary and commentary.
HEC88473 (Dual GLP-1/FGF21 Agonist): First-in-Human Phase 1 Findings
A phase 1 single-ascending-dose first-in-human trial of HEC88473, a dual GLP-1/FGF21 receptor agonist, reporting tolerability and early metabolic signals in healthy and obese adults. PICO summary and expert commentary.
Does SGLT2 Inhibitor Use Modify Oral Semaglutide’s Cardiovascular Benefit in Type 2 Diabetes?
A prespecified SOUL trial analysis tested whether baseline SGLT2 inhibitor use modified oral semaglutide's cardiovascular benefit in type 2 diabetes. PICO summary and expert commentary.
Once-Weekly Insulin Icodec in Type 2 Diabetes: Consistent Across GLP-1RA and SGLT2i Background Therapy
A post hoc analysis of ONWARDS 1-5 testing whether the efficacy and hypoglycaemia profile of once-weekly insulin icodec versus once-daily basal insulin differs by baseline GLP-1RA or SGLT2i use. PICO summary and expert commentary.
Once-Weekly Semaglutide 2.4 mg for Weight Loss in Chinese Adults: STEP 7 Analysis
Once-weekly semaglutide 2.4 mg cut body weight by an estimated 8.3% more than placebo over 44 weeks in Chinese adults with overweight or obesity in the STEP 7 trial. PICO summary and expert commentary.
Does iGlarLixi Improve Early Blood Sugar Control in Asians with Type 2 Diabetes?
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.